Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 256.50
Bid: 254.50
Ask: 255.50
Change: -4.00 (-1.54%)
Spread: 1.00 (0.393%)
Open: 267.00
High: 267.00
Low: 250.00
Prev. Close: 260.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading and COVID-19 Update

29 Apr 2020 07:00

RNS Number : 2338L
Synthomer PLC
29 April 2020
 

29th April 2020

 

Synthomer plc

Q1 Trading and COVID-19 Update

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2020.

Q1 Trading

As announced previously, the Group has experienced a solid start to the year with EBITDA approximately 5% ahead of the comparative Q1 period for the heritage business, and in line with expectations set out at the time of Synthomer's full year results announcement.

Performance Elastomers

Our Nitrile Butadiene Latex ('Nitrile') business continued to benefit from the additional 90kt of capacity introduced in Q4 2018 at our Pasir Gudang site. We saw higher volumes due to COVID-19, although unit margins were marginally lower relative to a strong comparative period in 2019. Styrene Butadiene Rubber ('SBR') market conditions stabilised with volumes in line and unit margins ahead of prior year. The strategic review of our European SBR network is ongoing and a further update will be provided in due course.

Functional Solutions

Whilst reported volumes were lower than the comparative period this was compensated for by stronger unit margins as a result of improved mix and softer raw material markets. Progress has been supported by the expansion of our Worms, Germany and Roebuck, USA dispersions facilities last year which introduced low cost capacity to drive organic growth in differentiated applications.

Industrial Specialities

Performance has continued in line with expectations. Excluding the impact of our acrylate monomer business, which largely supplies internal demand, all businesses made progress with volumes in line and margins ahead of the comparative period in 2019.

COVID-19 Update

The Group continues to operate 37 of its 38 global manufacturing sites, with speciality chemicals designated as key industrial assets in the geographies in which Synthomer operates. To date, the Group has experienced no significant issues with regards to raw material supply, the distribution of finished goods or the availability of operating personnel.

Notwithstanding Synthomer's broad geographic and end market diversity, Q2 sales into industrial markets including Automotive and the Oil & Gas sector are currently being impacted. However demand for Nitrile continues to be strong particularly as a result of the COVID-19 pandemic.

 

As previously announced, the Group has a strong balance sheet with significant leverage covenant headroom (4.25x and 4.00x EBITDA for 2020 and 2021), and significant liquidity underpinned by the 2024 committed unsecured 5 year €460m RCF and $260m term loan bank facilities.  

 

Synthomer expects to reduce its capital expenditure for 2020 to approximately £50m from the £73.5m originally anticipated (including OMNOVA). The Group has recently completed a material capital expenditure programme and its asset base remains well invested.

Under the current circumstances, the Group's Board, Executive and Senior Management have frozen their salaries at 2019 levels and delayed any further review until October 2020.

Following the completion of the OMNOVA transaction, as announced on the 1st April 2020, the ongoing integration of the business is progressing. We confirm delivery of the expected $29.6m synergy is on track. OMNOVA reported EBITDA Q1 2020 marginally ahead of Q1 2019 but given their exposure to a broad range of industrial markets expect an impact from the COVID-19 pandemic in the months ahead.

Outlook

Given the unprecedented uncertainty around the impact of COVID-19, it is unclear what impact this will have on the Group's financial performance for the year. As such, the Group is withdrawing its previous guidance for the year ending 31st December 2020 and will update the market when there is better visibility.

Over the medium term the Board remains confident that Synthomer is well positioned due to the Group's strong geographic and end market diversity combined with self-help initiatives and the future benefits to come from the successful acquisition and integration of OMNOVA.

-ENDS-

 

Enquiries:

 

Synthomer plc

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, President, Corporate Development

Tel: + 44 7764 859147

 

 

Teneo

Charles Armitstead / Matt Denham

Tel: + 44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEUFAAESSEEL
Date   Source Headline
12th Aug 20087:00 amRNSSale Completion
5th Aug 20089:42 amRNSBlocklisting Interim Review
1st Aug 200812:03 pmRNSHolding(s) in Company
21st Jul 20087:00 amRNSDisposal
27th Jun 20087:00 amRNSSale Completion
26th Jun 200810:17 amRNSHolding(s) in Company
18th Jun 200811:44 amRNSHolding(s) in Company
17th Jun 200810:12 amRNSDirector/PDMR Shareholding
16th Jun 20085:14 pmRNSDirector/PDMR Shareholding
16th Jun 200810:33 amRNSDirector/PDMR Shareholding
2nd Jun 20082:57 pmRNSBlocklisting Interim Review
30th May 20082:37 pmRNSSale Completion
15th May 20084:17 pmRNSResult of AGM
15th May 20087:00 amRNSTrading Update
9th May 20081:44 pmRNSHolding(s) in Company
24th Apr 20083:00 pmRNSAnnual Information Update
14th Apr 20084:43 pmRNSAnnual Report and Accounts
8th Apr 20089:55 amRNSDirector/PDMR Shareholding
7th Apr 20084:30 pmRNSHolding(s) in Company
14th Mar 200811:48 amRNSDirector/PDMR Shareholding
14th Mar 200811:46 amRNSDirector/PDMR Shareholding
12th Mar 20087:00 amRNSFinal Results
11th Feb 20082:40 pmRNSBlocklisting Interim Review
11th Feb 20087:01 amRNSDisposal
14th Dec 20077:00 amRNSPre-close Trading Statement
30th Nov 20073:37 pmRNSBlocklisting Interim Review
28th Nov 20072:46 pmRNSHolding(s) in Company
22nd Nov 20074:25 pmRNSDirector/PDMR Shareholding
24th Sep 200710:00 amRNSGroup Finance Director
6th Sep 20077:01 amRNSInterim Results
21st Aug 20077:00 amRNSBoard Appointments
14th Aug 20079:30 amRNSHolding(s) in Company
8th Aug 200712:16 pmRNSHolding(s) in Company
1st Aug 20077:01 amRNSPlant reorganisation
24th Jul 20072:05 pmRNSHolding(s) in Company
20th Jul 20073:50 pmRNSHolding(s) in Company
13th Jul 200712:47 pmRNSHolding(s) in Company
22nd Jun 200711:16 amRNSHolding(s) in Company
1st Jun 200711:25 amRNSBlocklisting Interim Review
1st Jun 20077:01 amRNSDivisional restructuring
29th May 20072:44 pmRNSHolding(s) in Company
17th May 20074:41 pmRNSResult of AGM
17th May 20077:01 amRNSAGM Statement
15th May 20074:29 pmRNSAnnual Report and Accounts
20th Apr 20079:40 amRNSAnnual Information Update
19th Apr 200712:47 pmRNSHolding(s) in Company
10th Apr 20075:26 pmRNSDirectorate Change
29th Mar 20074:37 pmRNSHolding(s) in Company
22nd Mar 200712:30 pmRNSDirectorate Change
12th Mar 20071:05 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.